The Kaplan–Meier curve tracks the estimated proportion of a study population that remains event-free over time. The median is identified at the time point where this estimated survival proportion reaches 50%. Because the curve incorporates censored observations rather than treating them as completed events, it can summarize follow-up data even when some participants remain event-free.
Censored observations provide partial information: a participant has not experienced the defined event by the end of follow-up or has left the study earlier. Survival analysis retains that participant’s event-free time without assigning an unobserved event date. This helps the estimated survival pattern reflect available follow-up while acknowledging that the final event time is unknown.
A median identifies the midpoint of observed or estimated survival experience, so it is less influenced by unusually long survival times than a measure based on an arithmetic average. This makes it an interpretable summary when survival times are skewed. It can therefore describe treatment, disease, or failure-time patterns without requiring the data to be symmetrically distributed.
Researchers can estimate the survival pattern for each patient group, treatment group, or risk-factor category and then compare the time at which each curve reaches 50%. A later median indicates that the midpoint of event-free follow-up occurs later in that group. The comparison can summarize differences in death, disease progression, or treatment failure across groups.
The analysis requires time-to-event information for each participant, including the follow-up duration and whether the defined event occurred. If the event was not observed, the record can be treated as censored at the available follow-up endpoint or departure time. These data support construction of a Kaplan–Meier curve and identification of its 50% survival point.
In clinical research, it can summarize time to death, disease progression, or treatment failure and support comparisons between treatments or patient groups. Epidemiological studies can use the same approach to compare risk-factor categories. Because it accommodates censored follow-up and skewed survival times, the measure provides a practical summary of time-to-event outcomes.